Logo wahanariau.com
  2. Israel

Israel

Index
Globenewswire

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference

Rabu, 07 Januari 2026 - 05:44:13 Wib
Globenewswire

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

Rabu, 24 Desember 2025 - 21:43:13 Wib
Globenewswire

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

Jumat, 19 Desember 2025 - 23:24:52 Wib
Globenewswire

Teva Releases Q4 2025 Aide Memoire

Sabtu, 13 Desember 2025 - 18:19:47 Wib
Globenewswire

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026

Sabtu, 13 Desember 2025 - 18:19:12 Wib
Globenewswire

Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Kamis, 11 Desember 2025 - 00:07:40 Wib
Globenewswire

Cellebrite Completes Acquisition of Corellium, Extending the Industry’s Most Advanced AI-Powered Digital Investigation Platform

Rabu, 03 Desember 2025 - 12:19:19 Wib
Globenewswire

Teva Receives European Commission Approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Rabu, 26 November 2025 - 04:34:43 Wib
Globenewswire

Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board

Senin, 24 November 2025 - 22:57:24 Wib
Globenewswire

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December

Ahad, 23 November 2025 - 03:32:24 Wib
Globenewswire

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges

Rabu, 19 November 2025 - 20:34:20 Wib
Globenewswire

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS

Kamis, 06 November 2025 - 03:32:51 Wib
Globenewswire

Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis

Senin, 03 November 2025 - 21:44:06 Wib
Globenewswire

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November

Ahad, 02 November 2025 - 01:12:03 Wib
Globenewswire

Cellebrite Appoints Holly Windham as General Counsel and Chief Compliance Officer

Kamis, 30 Oktober 2025 - 22:12:43 Wib
Globenewswire

Actor, Host, Artist and Anti-Human Trafficking Advocate Terry Crews to Headline Cellebrite C2C User Summit 2026

Rabu, 29 Oktober 2025 - 01:20:01 Wib
Globenewswire

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

Rabu, 22 Oktober 2025 - 02:44:29 Wib
Globenewswire

Cellebrite Expands Market Reach with Innovations in Agentic AI, Cloud and Device Virtualization for the Company’s Autumn 2025 Release

Rabu, 15 Oktober 2025 - 21:26:49 Wib
Globenewswire

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

Sabtu, 11 Oktober 2025 - 02:25:54 Wib
Globenewswire

Teva Releases Q3 2025 Aide Memoire

Sabtu, 27 September 2025 - 02:46:01 Wib
Globenewswire

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

Sabtu, 27 September 2025 - 02:45:20 Wib
Globenewswire

Patients Taking AUSTEDO XR® (deutetrabenazine) Extended-release Tablets Reported Symptom Improvement and High Satisfaction

Senin, 22 September 2025 - 02:25:11 Wib
Globenewswire

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Senin, 22 September 2025 - 02:24:05 Wib
Globenewswire

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual Meeting

Kamis, 18 September 2025 - 02:37:45 Wib
Globenewswire

Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September

Rabu, 03 September 2025 - 23:16:09 Wib